Omnipharm

Omnipharm is a specialty pharmaceutical company focused on the development of respiratory drug delivery systems and generic inhalation products. The company is best known for its expertise in Dry Powder Inhaler (DPI) technology and its successful development of generic versions of major respiratory treatments such as fluticasone/salmeterol. Following its acquisition by Mylan (now Viatris) in 2011, Omnipharm's technology and pipeline became a core component of the parent company's global respiratory franchise. The company's products are designed to provide cost-effective alternatives for the treatment of chronic conditions like asthma and COPD.